Non-Fiction Books:

State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. Biopharmaceutical Characterization

Sorry, this product is not currently available to order

Here are some other products you might consider...

State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. Biopharmaceutical Characterization

The NISTmAb Case Study
Click to share your rating 0 ratings (0.0/5.0 average) Thanks for your vote!

Format:

Hardback
Unavailable
Sorry, this product is not currently available to order

Description

The focus of this volume is the characterization of monoclonal antibodies (mAbs). The book focuses both on general aspects, techniques, and regulatory concerns common to any recombinant protein, as well as specific analytical results. Volume 2 therefore serves as both a foundational body of NISTmAb product knowledge as well as an evaluation of its suitability as an industry-appropriate reference material (RM).In Volume 1, a framework was presented, detailing what potential critical quality attributes (PCQAs) should be measured when developing mAbs; offering a risk-based approach to determining and quantifying PCQAs; specifying to what level PCQAs must be measured; and ultimately, explaining why it all matters. In Volume 2, the editors use that framework as a guide to deduce key biochemical and biophysical parameters of the NIST RM. The ultimate goal of Volume 2 is helping researchers have the clearest picture possible of the NIST RM specifically and mAb characterization in general.

Author Biography:

Dr. John E. Schiel received his B.S. (2004) and Ph.D.(2009) in Chemistry from the University of Nebraska-Lincoln, and is currently a research chemist in the NIST Biomolecular Measurement Division. Dr. Darryl L. Davis holds a doctorate in Medicinal Chemistry from the Philadelphia College of Pharmacy and Science. Currently he leads an analytical group within the discovery organization at Janssen R&D. Dr. Oleg V. Borisov earned a B.S. degree (with honors) in Chemistry at Moscow State University (1992), and received his Ph.D. in Chemistry from Wayne State University (1997), after which he completed his post-doctoral studies at Lawrence Berkeley National Laboratories (2000) and Pacific Northwest National Laboratories (2001). He is currently a Director at Novavax, Inc., developing methods and strategies for analysis and characterization of recombinant vaccines, based on nano- and virus-like particle technologies.
Release date NZ
September 1st, 2016
Audiences
  • Postgraduate, Research & Scholarly
  • Professional & Vocational
Contributors
  • Edited by Darryl L. Davis
  • Edited by John E. Schiel
  • Edited by Oleg V. Borisov
Country of Publication
United States
Illustrations
74 halftones; 35 line drawings; 74 halftones; 35 line drawings
Imprint
Oxford University Press Inc
Pages
448
Publisher
Oxford University Press Inc
Dimensions
162x232x34
ISBN-13
9780841230293
Product ID
25164354

Customer reviews

Nobody has reviewed this product yet. You could be the first!

Write a Review

Marketplace listings

There are no Marketplace listings available for this product currently.
Already own it? Create a free listing and pay just 9% commission when it sells!

Sell Yours Here

Help & options

Filed under...